• FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax americanpharmaceuticalreview
    June 26, 2019
    AbbVie announced the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on CANOVA (M13-494), a Phase 3 trial evaluating venetoclax (VENCLEXTA® OR VENCLYXTO®) for the investigational treatment of relapsed/refractory multipl
PharmaSources Customer Service